Business Insider

Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline

Strong Momentum in Dosing Patients and Manufacturing Clinical Supply for RTX-240 Phase 1/2 Solid Tumor Clinical Trial Investigational New Drug Application on Track by Year-End for RTX-321 for ...
CNN

Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update

CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ...
Reuters

Rubius Therapeutics Inc - Plan To File Investigational New Drug Application By End Of 2020."

Healthcare & Pharmaceuticalscategory Kennedy plans studies to look for environmental contributors to autism 4:48 PM UTC · Updated ago Healthcare & Pharmaceuticalscategory Baby food makers are failing ...
MedCity News

Rubius’s New Cell Therapy Strategy Runs Out of Time & Money; Workforce Is Cut by 82%

Rubius Therapeutics’ plan to revive its red blood cell therapy research with a new approach has run out of time and money, and the biotech is now looking to strike a deal to salvage what’s left of the ...
Business Insider

Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP ...